- News
- Published:
(2025)Cite this article
Merck’s new antibody clesrovimab and other long-lasting shots promise to both expand and simplify care of newborns across the world to combat respiratory syncytial virus.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
195,33 € per year
only 16,28 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Ethics declarations
Competing interests
A.M. is a consultant at Haystack Sciences and has no competing interests with the companies mentioned in this article.
Rights and permissions
About this article
Cite this article
Marshall, A., Nordling, L. Merck’s anti-RSV antibody expands protection for infants.
Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02713-w
-
Published:
-
DOI: https://doi.org/10.1038/s41587-025-02713-w
